Sitagliptin APOTEX sitagliptin 50 mg (as phosphate monohydrate) tablet blister pack

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

sitagliptin phosphate monohydrate, Quantity: 64.25 mg (Equivalent: sitagliptin, Qty 50 mg)

Dostępny od:

Arrotex Pharmaceuticals Pty Ltd

INN (International Nazwa):

sitagliptin phosphate monohydrate

Forma farmaceutyczna:

Tablet

Skład:

Excipient Ingredients: purified talc; magnesium stearate; hypromellose; iron oxide yellow; croscarmellose sodium; titanium dioxide; macrogol 8000; calcium hydrogen phosphate; hyprolose; iron oxide red; microcrystalline cellulose

Droga podania:

Oral

Sztuk w opakowaniu:

28

Typ recepty:

(S4) Prescription Only Medicine

Wskazania:

Sitagliptin is indicated for the treatment of diabetes mellitus type 2 in persons 18 years of age and older who have failed dietary measures and exercise:,- as monotherapy, as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus, when metformin cannot be used.,- as dual combination therapy, with metformin, or with a sulfonylurea, or with a thiazolidinedione where the use of a thiazolidinedione is considered appropriate.,- as triple combination therapy with metformin and a sulfonylurea when combination therapy with both agents does not provide adequate glycaemic control.,- as add-on combination therapy with insulin (with or without metformin).

Podsumowanie produktu:

Visual Identification: Light beige, round, biconvex coated tablet. Engraved "SIT" over "50" on one side and "APO" on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Status autoryzacji:

Licence status A

Data autoryzacji:

2015-04-15